Last $0.88 SGD
Change Today +0.005 / 0.57%
Volume 1.2M
BIG On Other Exchanges
As of 12:12 AM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

biosensors international gro (BIG) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/25/13 - $1.07
52 Week Low
12/31/13 - $0.80
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

biosensors international gro (BIG) Related Businessweek News

No Related Businessweek News Found

biosensors international gro (BIG) Details

Biosensors International Group, Ltd., an investment holding company, develops, manufactures, and markets various medical devices for interventional cardiology and critical care procedures in China, Japan, and internationally. The company operates in four segments: Interventional Cardiology, Critical Care, Cardiac Diagnostic, and Licensing Revenue. The Interventional Cardiology segment supplies proprietary drug-eluting stents, coronary bare-metal stents, accompanying stent delivery balloon catheter systems, angioplasty balloons, and catheters under the BioMatrix Flex, BioMatrix NeoFlex, Axxess, BioFreedom, Chroma, Gazelle, Biostream, Biopath, and Powerline brands. The Critical Care segment supplies catheter systems and related accessories that are used in surgeries, and intensive care treatment and monitoring procedures. This segment offers ACCUTRANS, a disposable blood pressure transducer system; BIOTRANS, a re-usable blood pressure transducer; Multi-Lumen central venous catheters for infant and adult patients to administer medication or fluids, obtain blood tests, and directly obtain cardiovascular measurements; Thermodilution and Pulmonary Artery catheters for pulmonary artery monitoring; Bipolar Pacing catheters for temporary transvenous cardiac pacing to support critical procedures in the catherization lab, CCU, and emergency room settings; Embolectomy catheters; and BIOTRAY devices. The Cardiac Diagnostic segment supplies medical imaging and clinical applications. The Licensing Revenue segment is engaged in the licensing of its proprietary drug-eluting stent technology and intellectual property. The company was founded in 1990 and is headquartered in Singapore.

Founded in 1990

biosensors international gro (BIG) Top Compensated Officers

Founder, Executive Chairman, Interim Chief Ex...
Total Annual Compensation: $1.4M
Chief Operating Officer and Executive Directo...
Total Annual Compensation: $94.0K
President of Cardiovascular Business Unit
Total Annual Compensation: $2.5M
Chief Technology Officer and Executive Direct...
Total Annual Compensation: $988.0K
Compensation as of Fiscal Year 2014.

biosensors international gro (BIG) Key Developments

Biosensors Announces Earnings Results for the Year Ended March 31, 2014

Biosensors announced earnings results for the year ended March 31, 2014. For the fiscal 2014, Biosensors reported a revenue of USD 323.8 million, down 4% year-on-year as product revenue growth was offset by lower licensing and royalty revenue. Net profit for the financial year ended March 31, 2014, worked out to USD 40.6 million (including exceptional items), down from USD 115.5 million previously.

Biosensors International Group, Ltd. Presents at Healthcare Corporate Day l, Jul-16-2014

Biosensors International Group, Ltd. Presents at Healthcare Corporate Day l, Jul-16-2014 . Venue: Hong Kong, Hong Kong.

Biosensors International Group, Ltd., Annual General Meeting, Jul 24, 2014

Biosensors International Group, Ltd., Annual General Meeting, Jul 24, 2014., at 10:00 Singapore Standard Time. Location: Level 3, Meeting Room 300. Agenda: To receive and adopt the statement by directors and the audited financial statements of the company for the financial year ended March 31, 2014 together with the independent auditors report thereon; to re-elect directors; to record the retirement of Dr. Jack WANG pursuant to Bye-law 104 of the Company's Bye-laws, who has decided not to seek for re-election; to approve the payment of directors fees of up to SGD 600,000 for the financial year ending March 31, 2015; to re-appoint Ernst & Young LLP as auditors of the company for the ensuing year and to authorize the directors to fix their remuneration; and to transact any other ordinary business which may properly be transacted at an AGM.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIG:SP $0.88 SGD +0.005

BIG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $13.26 USD +0.24
View Industry Companies

Industry Analysis


Industry Average

Valuation BIG Industry Range
Price/Earnings 29.8x
Price/Sales 3.7x
Price/Book 1.0x
Price/Cash Flow 30.4x
TEV/Sales 1.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOSENSORS INTERNATIONAL GRO, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at